No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Enliven Therapeutics Down Over 12%, On Pace for Largest Percent Decrease Since November 2022 -- Data Talk
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $39
Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Enliven Therapeutics Analyst Ratings